KFBIO Raises Over RMB 100 Million in Series C Financing to Accelerate Digital Pathology Innovation

KFBIO has successfully completed its first Series C financing round, raising more than RMB 100 million. The investment was led by WISDOMONT Capital. This milestone marks an important step in KFBIO’s growth. It will accelerate product innovation, strengthen digital pathology solutions, and support the company’s global expansion.

A Decade of Focus on Digital Pathology

Founded in 2011, KFBIO has focused exclusively on digital pathology for more than a decade. Today, it is one of China’s leading providers of digital pathology products and services.

KFBIO delivers end-to-end digital pathology solutions for hospitals, laboratories, and research institutions. Guided by its philosophy of “Root in Pathology, Focus on Pathology, Dive into Pathology, and Serve Pathology,” the company continues to drive innovation across the pathology industry.

Building a Complete Digital Pathology Portfolio

Over the years, KFBIO has developed a comprehensive portfolio that supports the entire pathology workflow.

Its solutions include:

• Routine pathology equipment
• Digital pathology scanners
• Pathology AI products
• Pathology information systems
• Smart pathology laboratories

Together, these products help laboratories improve efficiency, standardize workflows, and accelerate digital transformation.

Why Digital Pathology Matters

Pathologists play a critical role in modern healthcare. Their diagnoses are widely recognized as the gold standard for disease diagnosis.

However, many healthcare systems still face major challenges. These include limited pathology resources, uneven resource distribution, and low levels of digitalization and intelligence.

As a result, digital pathology has become one of the fastest-growing areas in healthcare. It offers new opportunities to improve diagnostic efficiency, expand access to pathology expertise, and support AI-assisted diagnosis.

Recognizing this trend, KFBIO continues to invest in technologies that advance pathology digitization, automation, and intelligence.

Driving Digital Transformation in Leading Hospitals

KFBIO has successfully implemented digital pathology projects in many of China’s leading hospitals.

For example, the company has worked with:

• West China Hospital
• Henan Provincial People’s Hospital
• Sichuan Cancer Hospital

In addition, KFBIO has partnered with well-known regional pathology centers, including:

• Dongguan Pathology Center
• Ningbo Pathology Center

These successful projects demonstrate KFBIO’s ability to build fully digital pathology departments. They also support the broader adoption of digital pathology across China and beyond.

A Strong Foundation for Future Growth

Today, KFBIO continues to expand its digital pathology ecosystem through technology innovation and close collaboration with healthcare partners.

With a growing portfolio of products and successful large-scale deployments, the company is well positioned to accelerate the global development of digital pathology.

Trusted by More Than 2,000 Hospitals

KFBIO has established a strong position in China’s high-end digital pathology market. For many years, the company has remained one of the industry’s leading providers.

Today, more than 2,000 hospitals use KFBIO products. Their positive feedback reflects the company’s commitment to product quality, innovation, and customer support.

Strong R&D Capabilities and Industry Certifications

KFBIO’s success is built on continuous research and development. Backed by years of technical expertise, the company has developed a complete portfolio covering pathology equipment, digital pathology, and AI-powered solutions.

In addition, KFBIO has obtained a wide range of industry certifications.

These include:

• China’s first CFDA approval for a deep learning-based pathology AI product (2019)
• CE certification for digital pathology scanners
• Multiple software and product certifications across pathology applications

Furthermore, KFBIO has built a comprehensive product portfolio that supports both cytology and histology workflows.

Working with Industry-Leading Partners

Innovation requires collaboration. Therefore, KFBIO works closely with leading healthcare and technology organizations to advance digital pathology.

Its strategic partners include:

• China Maternal and Child Health Association
• Huawei
• Intel
• H3C

Together, these partnerships accelerate technology development and promote the practical adoption of digital pathology solutions.

Expanding Across Global Markets

In recent years, KFBIO has continued to strengthen its international presence. High-quality products and strong independent R&D capabilities have supported this rapid growth.

Today, KFBIO serves customers across Europe, the Americas, Asia, and Oceania.

Its products are used in countries including:

• Thailand
• Pakistan
• Türkiye
• Brazil
• Chile
• Australia
• Russia

For example, KFBIO has supported cervical cancer screening programs for tens of thousands of women in Brazil.

Looking ahead, the company aims to achieve balanced revenue growth across both domestic and international markets within the next three to five years.

As global demand for digital pathology continues to grow, overseas markets are expected to become an important driver of KFBIO’s long-term development.

Executive Perspectives

WISDOMONT Capital: Confidence in KFBIO’s Future

Dr. Cheng Hao, General Manager of WISDOMONT Capital, spoke highly of KFBIO’s achievements.

“KFBIO is an innovative high-tech company in the digital pathology industry. Over the past decade, it has built a complete product portfolio covering routine pathology equipment, digital pathology scanners, and pathology AI products. We are pleased to partner with KFBIO and will fully support its journey toward becoming a world-leading digital pathology company.”

KFBIO: Driving the Future of Digital Pathology

Mr. Liu Bingxian, Chairman and General Manager of KFBIO, shared the company’s long-term vision.

“KFBIO has always remained committed to pathology. Guided by our philosophy of serving pathology, we continue to integrate AI, big data, and AIoT technologies into our products and solutions.

Today, we provide end-to-end digital pathology solutions covering digital pathology scanners, routine pathology equipment, pathology information management systems, pathology AI products, and pathology diagnostic services.

Looking ahead, we will continue to support the Healthy China strategy, promote high-quality development across the pathology industry, and accelerate the global adoption of digital pathology.”

Looking Ahead

The successful completion of KFBIO’s first Series C financing marks the beginning of a new stage of growth.

Moving forward, the company will continue to invest in innovation, expand its global footprint, and strengthen its end-to-end digital pathology ecosystem.

With advanced technologies, comprehensive solutions, and strong strategic partnerships, KFBIO is well positioned to help hospitals and laboratories accelerate digital transformation and improve pathology services worldwide.